HONG KONG – Encouraged by new policies to boost drug development, biopharmaceutical companies in China are increasingly investing in innovative drugs overseas that are at late R&D stages and bringing the candidates to the domestic market for further clinical studies.
BOSTON – The triumph of the Massachusetts Institute of Technology Broad Institute and its spinout company Editas Medicine Inc. in the case of CRISPR/Cas9 gene editing patents could impede the development of human therapies based on the technology, according to one of the leading researchers in the field.
In a single sentence, the U.S. PTO rendered a judgment of "no interference-in-fact" in CRISPR/Cas9 interference motion phase, neither canceling nor finally refusing the claims of either party.
- Sweet deal for Gilead? Firm snaps up Sarepta's PRV for $125M cash
- Trevena sinks on commercial worries despite phase III APOLLO success
- Cidara sayonara to topical VVC echinocandin leaves I.V. wait-and-see about read-throughs
- Apollobio to bring Inovio's new HPV drug to China marketplace
- Chi-Med's savolitinib hits phase II endpoints in...
- Beijing's Apollobio to bring Inovio's new HPV drug to China marketplace
- Chi-Med's savolitinib hits phase II endpoints in Met-driven PRCC
- Samsung's biosimilars come to fruition despite scandals, company says
- Germline gene editing should be allowed – in certain situations
- Tivantinib misses OS endpoint in phase III liver...
Although the world-famous groundhog Punxsutawney Phil awoke to see his shadow at the beginning of the month, predicting a further six weeks of winter, thanks to President Donald Trump's vow of a major impending tax announcement, it looks as though biopharmaceutical companies will enjoy an early spring. Their stocks have surged more than 4 percent so far this month in lockstep with the bullish general markets that have hit record highs, with investors believing that the new administration's plans for tax reforms will expand the economy.
LONDON Clinical trials involving genome editing in gametes or early embryos could be permitted in the future, but only for serious conditions and under stringent oversight, said experts after a year-long review of the scientific and ethical issues thrown up by CRISPR/Cas9.READ MORE »
- Screening a risky, beneficial business »
- Bacterial immunotherapy shows promise in tumor-targeting »
- 'Bioinspired' culturing process loses serum, gains reproducibility »
- First rotaviruses derived entirely from cloned DNA developed »
- Clotting, hypertension, inflammation linked »
- Plant-derived products may help fight HBV »
- New targets for overcoming melanoma resistance identified »
- Dual-action, dual-indication decoy fights tumors, viruses »
- Stem cell-based model suggests deafness treatments »
- Is ‘what the patient pays’ the right barometer for pricing drugs?January 26, 2017 | 5:08 PM | Posted by: Mari Serebrov
- Yes, there’s a doctor in the House (and Senate)January 04, 2017 | 12:21 AM | Posted by: Mari Serebrov
- Time for fa-la-la with BioWorld’s 10th annual Holiday Gift GuideDecember 02, 2016 | 8:43 PM | Posted by: Marie Powers
- Biotech’s biggest protesters are turning into its supporters November 30, 2016 | 10:58 PM | Posted by: Amanda Lanier
- Sex and drugs: Something doesn’t ‘Addyi’ upNovember 04, 2016 | 10:35 PM | Posted by: Randy Osborne
Partners in Focus
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST